Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Email Website Social Media Number of Employees Founded (year) Areas of Activity
iOmx Therapeutics AG
First-in-class immuno-oncology drugs targeting novel cancer immune evasion mechanisms. iOmx Therapeutics AG was founded in 2016 and focuses on the development of first-in-class, next-generation cancer immuno-therapy drugs, which are designed to neutralise the inhibitory function of novel tumour or tumour-associated myeloid cell-expressed immunecheckpoint modulators.
›
Fraunhoferstr. 13 82152 Martinsried Germany Dr Apollon Papadimitriou +49-89-8999-7090-0 info@iomx.com www.iomx.com
›
I
While the currently approved immune-checkpoint inhibitory drugs targeting CTLA-4, PD-1, or PD-L1 pathways have emerged as the standard of care in many tumour indications, they still do not meet the needs of most cancer patients, primarily due to inherent, nonredundant resistance mechanisms of tumours against immune cell attack.
›
› › › › › ›
› ›
›
30 2016 | Next-generation cancer immunotherapies | Drug development | Immuno-oncology
Platform Overview In order to discover and understand alternative druggable vulnerabilities in such immunosuppressive tumours, iOmx Therapeutics efficiently applies its proprietary iOTarg™ target discovery platform, a systematic highthroughput genetic screening approach, to identify and validate novel immune-checkpoint targets in cancer models that fail to respond to PD-L1 inhibition. To date, this screening technology has been applied to several pairs of clinical tumour samples and tumourinfiltrating lymphocytes (TILs), resulting in the identification of multiple novel targets, which exhibit stronger inhibition of T cell-mediated killing than PD-L1 in classic assays. To further extend the iOmx pipeline, an evolved version of the screening platform is currently being applied to identify and validate novel checkpoint targets in tumourassociated myeloid cells. Overall, the iOTarg™ platform points the way to next-generation immunotherapy approaches that are designed to increase the clinical impact of immunecheckpoint therapies.
